Meta-analysis of efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection of bladder tumors
- 47 Downloads
We performed a meta-analysis to confirm the efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection for the treatment of non-muscle invasive bladder cancer.
Randomized controlled trials of continuous saline bladder irrigation compared with intravesical chemotherapy were searched using MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. The data were evaluated and statistically analyzed using RevMan version 5.3.0.
Four studies including 861 participants which compared continuous saline bladder irrigation with intravesical chemotherapy were considered. One-year recurrence-free survival [odds ratio (OR) = 0.76, 95% CI = 0.55–1.05, p = 0.09]; 2-year recurrence-free survival (OR = 0.94, 95% CI = 0.71–1.25, p = 0.68); the median period to first recurrence (OR = − 1.01, 95% CI = − 2.96 to 0.94, p = 0.31); the number of tumor progression (OR = 0.80, 95% CI = 0.54–1.17, p = 0.25); and the number of recurrence during follow-up (OR = 1.12, 95% CI = 0.84–1.50, p = 0.43) suggested that two methods of postoperative perfusion had no significant differences. In terms of safety, including macrohematuria, frequency of urination and bladder irritation symptoms, continuous saline bladder irrigation showed better tolerance than intravesical chemotherapy.
Continuous saline bladder irrigation seems to provide a better balance between prevention of recurrence and local toxicities than intravesical chemotherapy after transurethral resection of bladder tumors.
KeywordsNon-muscle invasive bladder cancer Meta-analysis Randomized controlled trials Continuous saline bladder irrigation Transurethral resection of bladder tumors
DY and YC participated in the design of this study. JW performed the statistical analysis. YL and YL collected important background information. ZZ and SZ drafted the manuscript. ZG conceived this study, participated in the design and helped to draft the manuscript. All authors read and approved the final manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Ethics approval and consent to participate
The authors have no ethical conflicts to disclose.
- 5.Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M, Buckley R, Soloway M, Akaza H, Bohle A (2011) A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 186(6):2158–2167CrossRefGoogle Scholar
- 8.Nojiri Y, Okamura K, Kinukawa T, Ozawa H, Saito S, Okumura K, Terai A, Takei M (2007) Continuous bladder irrigation following transurethral resection of the prostate (TURP). Nihon Hinyokika Gakkai Zasshi 98(6):770–775Google Scholar
- 10.Jadad AR (1998) Randomised controlled trials. BMJ Publishing Group, LondonGoogle Scholar
- 11.Higgins JP, Green S (2011) Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The Cochrane collaboration. Updated Mar 2011. http://www.cochrane-handbook.org. Cited 10 May 2017
- 13.Maekawa S, Suzuki H, Ohkubo K, Aoki Y, Okada T, Maeda H, Ogura K, Arai Y (2000) Continuous intravesical instillation of epirubicin immediately after transurethral resection of superficial bladder cancer: a prospective controlled study. Hinyokika kiyo Acta Urologica Japonica 46(5):301–306Google Scholar
- 14.Bohle A, Leyh H, Frei C, Kuhn M, Tschada R, Pottek T, Wagner W, Knispel HH, von Pokrzywnitzki W, Zorlu F, Helsberg K, Lubben B, Soldatenkova V, Stoffregen C, Buttner H (2009) Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. Eur Urol 56(3):495–503CrossRefGoogle Scholar
- 15.Onishi T, Sasaki T, Hoshina A, Yabana T (2011) Continuous saline bladder irrigation after transurethral resection is a prophylactic treatment choice for non-muscle invasive bladder tumor. Anticancer Res 31(4):1471–1474Google Scholar
- 17.Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466–477CrossRefGoogle Scholar
- 20.Sylvester RJ, Oosterlinck W, van der Meijden A (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171:2186–2190CrossRefGoogle Scholar
- 21.Gudjonsson S, Adell L, Merdasa F, Olsson R, Larsson B, Davidsson T, Richthoff J, Hagberg G, Grabe M, Bendahl PO, Mansson W, Liedberg F (2009) Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 55(4):773–780CrossRefGoogle Scholar
- 24.Oosterlinck W, Kirkali Z, Sylvester R, da Silva FC, Busch C, Algaba F, Collette S, Bono A (2011) Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guerin and with bacillus Calmette-Guerin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993). Eur Urol 59:438–446CrossRefGoogle Scholar
- 25.Chen L, Pan XW, Huang H, Gao Y, Yang QW, Wang LH, Cui XG, Xu DF (2017) Epithelial-mesenchymal transition induced by GRO-alpha-CXCR2 promotes bladder cancer recurrence after intravesical chemotherapy. Oncotarget 8(28):45274–45285Google Scholar
- 27.Lenis AT, Asanad K, Blaibel M, Donin NM, Chamie K (2018) Continuous saline bladder irrigation for two hours following transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer does not prevent recurrence or progression compared with intravesical Mitomycin-C. BMC Urol 18(1):93CrossRefGoogle Scholar